<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03530397</url>
  </required_header>
  <id_info>
    <org_study_id>D7980C00001</org_study_id>
    <nct_id>NCT03530397</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate MEDI5752 in adult subjects with advanced solid
      tumors, when administered as a single agent or combined with chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, first-time-in-human, multicenter, open-label, dose-escalation and
      dose-expansion study to evaluate the safety and tolerability, and efficacy, pharmacokinetics
      and Immunogenicity of MEDI5752 in adult subjects with advanced solid tumors, when
      administered as a single agent or combined with chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">July 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects experiencing treatment related adverse events (AEs).</measure>
    <time_frame>From the time of informed consent through 114 days following termination of treatment with investigational product</time_frame>
    <description>The primary endpoint is as assessed by the number of subjects experiencing adverse events (AEs) graded per NCI CTCAE v4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preliminary anti-tumor activitiy of MEDI5752 (versus pembrolizumab, where applicable) using Objective Response based on RECIST v1.1 (Dose-Expansion Phase)</measure>
    <time_frame>From the first dose of study drug through the date of first documented progression, end of study, date of death, or two years after the last patient starts treatment, whichever should occur first</time_frame>
    <description>The primary endpoint of antitumor activity include Objective Response and will be based on all post baseline disease assessments that occur prior to initiation of subsequent anticancer therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects experiencing dose-limiting toxicities (DLTs)</measure>
    <time_frame>Up to 21 days following the first dose</time_frame>
    <description>The primary endpoint is as assessed by the number of subjects experiencing dose limiting toxicities (DLTs) as defined by the protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in laboratory evaluations.</measure>
    <time_frame>From the time of informed consent through 30 days following termination of treatment with investigational product</time_frame>
    <description>The primary endpoint is as assessed by the change in laboratory parameters from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in vital signs</measure>
    <time_frame>From the time of informed consent through 14 days following termination of treatment with investigational product</time_frame>
    <description>The primary endpoint is as assessed by the change in vital signs from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in ECGs</measure>
    <time_frame>From the time of informed consent through 14 days following termination of treatment with investigational product</time_frame>
    <description>The primary endpoint is as assessed by the change in ECG parameters from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects experiencing treatment related serious adverse events (SAEs).</measure>
    <time_frame>From the time of informed consent through 114 days following termination of treatment with investigational product</time_frame>
    <description>The primary endpoint is as assessed by the number of subjects with serious adverse events (SAEs) graded per NCI CTCAE v4.03.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI5752: Cmax</measure>
    <time_frame>To be assessed at Day 1, 2, 3, 8, 15, 22, 29, 43, 64, 85, and 106 over the first 4 months of treatment and up to 114 days following end of treatment</time_frame>
    <description>The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration. PK parameters that may be modeled on this data include maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI5752: AUC</measure>
    <time_frame>To be assessed at Day 1, 2, 3, 8, 15, 22, 29, 43, 64, 85, and 106 over the first 4 months of treatment and up to 114 days following end of treatment</time_frame>
    <description>The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration. PK parameters that may be modeled on this data include area under the concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI5752: Clearance</measure>
    <time_frame>To be assessed at Day 1, 2, 3, 8, 15, 22, 29, 43, 64, 85, and 106 over the first 4 months of treatment and up to 114 days following end of treatment</time_frame>
    <description>The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration. PK parameters that may be modeled on this data include clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI5752: t 1/2</measure>
    <time_frame>To be assessed at Day 1, 2, 3, 8, 15, 22, 29, 43, 64, 85, and 106 over the first 4 months of treatment and up to 114 days following end of treatment.</time_frame>
    <description>The endpoints for the assessment of PK of MEDI5752 include individual MEDI5752 concentrations at different time points after administration. PK parameters that may be modeled on this data include terminal phase half life (t 1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of MEDI5752</measure>
    <time_frame>To be assessed at Day 1, 8, 15, 22, 29, 43, 64, 85, and 106 over the first 4 months of treatment and up to 114 days following end of treatment.</time_frame>
    <description>The endpoints for the immunogenicity of MEDI5752 include the number of subjects who develop detectable anti-drug antibodies (ADAs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1 Expression in subjects with advanced solid tumors</measure>
    <time_frame>To be assessed at at baseline</time_frame>
    <description>The endpoint for the PD-L1 expression will be determined by Immunohistochemistry characterization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Antitumor Activity: Duration of Response</measure>
    <time_frame>From the date of response through the date of first documented progression, end of study, date of death, or two years after last subject starts treatment whichever should occur first</time_frame>
    <description>The endpoints for assessment of antitumor activity include duration of response (DoR) and is defined as the duration from the documentation of OR to the first documentation of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Antitumor Activity: Disease Control</measure>
    <time_frame>From the first dose of study drug through the date of first documented progression, end of study, date of death, or two years after last subject starts treatment whichever should occur first</time_frame>
    <description>The endpoints for assessment of antitumor activity include disease control (DC) and is defined as CR, PR, or SD according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Antitumor Activity: Progression Free Survival</measure>
    <time_frame>From the first dose of study drug through the date of first documented progression, end of study, date of death, or two years after last subject starts treatment whichever should occur first</time_frame>
    <description>The endpoints for assessment of antitumor activity include progression free survival (PFS) and is defined as the duration measured from the start of treatment with investigational product to the first documentation of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Antitumor Activity: Overall Survival</measure>
    <time_frame>From the first dose of study drug through the end of study, or date of death, or two years after last subject starts treatment whichever should occur first</time_frame>
    <description>The endpoints for assessment of antitumor activity include overall survival (OS) and is defined as the duration measured from the start of treatment with investigational product until death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Selected Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A: MEDI5752</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI5752</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: MEDI5752 and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI5752, pemetrexed and carboplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Pembrolizumab and chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pembrolizumab, pemetrexed, and carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI5752</intervention_name>
    <description>Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.</description>
    <arm_group_label>Arm A: MEDI5752</arm_group_label>
    <arm_group_label>Arm B: MEDI5752 and chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation</description>
    <arm_group_label>Arm B: MEDI5752 and chemotherapy</arm_group_label>
    <arm_group_label>Arm C: Pembrolizumab and chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation</description>
    <arm_group_label>Arm B: MEDI5752 and chemotherapy</arm_group_label>
    <arm_group_label>Arm C: Pembrolizumab and chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation</description>
    <arm_group_label>Arm C: Pembrolizumab and chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age ≥ 18 years at the time of screening

          2. World Health Organization/Eastern Cooperative Oncology Group (ECOG) performance status
             of 0 or 1 at enrollment

          3. Life expectancy ≥ 12 weeks

          4. Histologically or cytologically-confirmed advanced solid tumors

          5. Subjects who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy or any
             concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy
             for cancer treatment may be eligible to enter the study following a washout period as
             applicable

          6. Females of childbearing potential who are sexually active with a nonsterilized male
             partner must use at least one highly effective method of contraception

          7. Nonsterilized males who are sexually active with a female partner of childbearing
             potential must use a male condom with spermicide where locally available from Day 1
             and for 90 days after the final dose of investigational product. Males receiving
             pemetrexed must use contraception during study treatment and up to 6 months
             thereafter.

          8. Subjects must have at least one measurable lesion

          9. Adequate organ and marrow function

         10. Written informed consent and any locally required authorization

         11. Subjects must provide tumor material as applicable

        Exclusion Criteria

          1. Involvement in the planning and/or conduct of the study (applies to both MedImmune
             staff and/or staff at the study site)

          2. Concurrent enrollment in another clinical study, unless it is an observational
             clinical study or the follow-up period of an interventional study

          3. For subjects who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4:

               1. Subjects must not have received anti-PD-1, anti-PD-L1, anti-CTLA-4 or any other
                  immunotherapy or immune-oncology (IO) agent within 21 days of commencing
                  treatment with investigational product.

               2. Subject must not have experienced a toxicity that led to permanent
                  discontinuation of prior immunotherapy.

               3. All AEs while receiving prior immunotherapy must have completely resolved or
                  resolved to Grade 1 prior to screening for this study.

          4. Current or prior use of immunosuppressive medication within 14 days before the first
             dose of investigational product is excluded.

          5. Receipt of live attenuated vaccine within 30 days prior to the first dose of
             investigational product.

          6. Active or prior documented autoimmune or inflammatory disorders

          7. History of active primary immunodeficiency:

          8. History of organ transplant

          9. Known allergy or reaction to any component of the planned study treatment.

         10. Untreated CNS metastatic disease, leptomeningeal disease, or cord compression

         11. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to
             NCI CTCAE v4.03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion
             criteria

         12. Major surgical procedure (as defined by the investigator) within 28 days prior to the
             first dose of Investigational Product or still recovering from prior surgery

         13. Female subjects who are pregnant or breastfeeding, as well as male or female subjects
             of reproductive potential who are not willing to employ one highly effective method of
             birth control

         14. Uncontrolled intercurrent illness, that would limit compliance with study requirement,
             substantially increase risk of incurring AEs or compromise the ability of the subject
             to give written informed consent.

         15. Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the investigational product or interpretation of the subject's safety or
             study results

         16. Judgment by the investigator that the subject is unsuitable to participate in the
             study and the subject is unlikely to comply with study procedures, restrictions, and
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepa Subramaniam, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Randwick</city>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju-si</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>﻿08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumors</keyword>
  <keyword>MEDI5752</keyword>
  <keyword>immuno-oncology</keyword>
  <keyword>Cancer</keyword>
  <keyword>PD-1/CTLA-4 Bispecific</keyword>
  <keyword>PD-1</keyword>
  <keyword>CTLA-4</keyword>
  <keyword>Bispecific</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Pembrolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

